Business
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))
New delivery system targets rapid-onset relief for motion sickness and vertigo, modernizing the $450M global market for the active ingredient in Dramamine®. Meclizine was the top-prescribed antiemetic/antivertigo agent in 2023, with approximately ...
About this update from Aspire Biopharma Holdings, Inc.
[{"type":"text","content":"New delivery system targets rapid-onset relief for motion sickness and vertigo, modernizing the $450M global market for the active ingredient in Dramamine®.","length":164,"tagName":"p"},{"type":"text","content":"Meclizine was the top-prescribed antiemetic/antivertigo agent in 2023, with approximately 4.09 million prescriptions.","length":117,"tagName":"p"},{"type":"text","content":"ESTERO, FL / ACCESS Newswire / February 17, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its proprietary sublingual powder formulation of Meclizine.","length":416,"tagName":"p"},{"type":"text","content":"The application, titled "A Sublingual Powder Formulation of Meclizine and Methods of Use Thereof," represents a significant leap in antiemetic therapy. By introducing the first-ever sublingual powder delivery system for Meclizine, Aspire aims to eliminate the traditional "waiting period" associated with oral tablets, providing near-instant relief for nausea, vomiting, and vertigo.","length":403,"tagName":"p"},{"type":"text","content":"Solving the One-Hour DelayWhile Meclizine remains the gold standard for vestibular disorders, traditional tablet forms are hindered by a slow onset of action. Standard oral administration typically requires one hour to begin working and up to three hours to reach peak plasma levels. Aspire's sublingual platform is engineered to redefine this standard through:","length":366,"tagName":"p"},{"type":"text","content":"Rapid Systemic Entry: By bypassing the gastrointestinal tract and first-pass metabolism, the formulation is designed to reduce the onset of action from 60 minutes to mere minutes. NIH","length":183,"tagName":"p"},{"type":"text","content":"Enhanced Patient Compliance: The powder format provides a critical solution for patients suffering from severe emesis (vomiting) or gastric irritation who cannot tolerate swallowing traditional pills.","length":200,"tagName":"p"},{"type":"text","content":"Strategic Market OpportunityAs the top-prescribed antiemetic of 2023 with over 4.09 million prescriptions in the U.S. alone, Mecli...